Cheuk Ngen Chin1, Azhar Zain2, Solaphat Hemrungrojn3, Eng Khean Ung4, Patanon Kwansanit5, Koon Choong Au Yong6, Marvin Swee Woon Chong7, Chalowat Inpa8, Teck Hoe Yen9, Boon Beng David Yeoh10, Liam Kai Tay11, Carmina Bernardo12, Lionel Chee-Chong Lim13, Chin Hong Yap14, Calvin Fones15, Ashwini Nayak16, Lars Nelleman16. 1. a Klinik Pakar C N Chin Sdn Bhd, CMH Medical Center , Kuala Lumpur , Malaysia. 2. b KPJ Ampang Puteri Specialist Hospital , Selangor , Malaysia. 3. c Chulalongkorn Hospital , Bangkok , Thailand. 4. d Adam Road Medical Centre, Singapore, Singapore. 5. e Somdejchaopraya Psychiatry Institute , Bangkok , Thailand. 6. f Klinik Pakar Au Yong , Kuala Lumpur , Malaysia. 7. g Hospital Fatimah , Ipoh , Malaysia. 8. h Somdejphrachaotaksin Hospital , Muang Tak , Thailand. 9. i Neuropsy Clinic Sdn Bhd , Chinese Maternity Hospital , Kuala Lumpur , Malaysia. 10. j Yeoh Psychiatric Clinic, Mahkota Medical Centre , Melaka , Malaysia. 11. k Dr Tay Liam Kai Psychiatric Care Clinic, Mount Elizabeth Novena Specialist Centre , Singapore , Singapore. 12. l Mood and Anxiety Resource and Referral Center, Makati Medical Center , Makati , Philippines. 13. m L P Clinic Pte Ltd , Mount Elizabeth Medical Centre , Singapore , Singapore. 14. n Yap Psychiatry Specialist Clinic S/B , Kuching , Malaysia. 15. o Fones Clinic, Gleneagles Medical Centre , Singapore , Singapore. 16. p Lundbeck Singapore Pte Ltd , Singapore.
Abstract
OBJECTIVE: The REVIDA study aimed to assess the evolution of major depression symptoms in South East Asian (SEA) patients treated with vortioxetine for major depression in real-world clinical practice. METHODS: This non-interventional study was conducted from August 2016 to April 2017. A total of 138 patients (aged 18-65 years) with an active episode of major depression were recruited from Malaysia, Philippines, Singapore and Thailand. Vortioxetine was initiated on the first visit and patients were followed for 3 months. Depression severity was assessed using the PHQ-9 questionnaire (patient assessed) and CGI-S scale (physician assessed); cognitive function was assessed with the PDQ-D questionnaire; work productivity and activity impairment (WPAI) was assessed with the WPAI questionnaire. RESULTS: At baseline, 89.9% of patients were moderately to severely depressed (PHQ-9 score ≥10). During the 3 month treatment period, mean ± SD PHQ-9 score decreased from 18.7 ± 5.7 to 5.0 ± 5.3, mean ± SD CGI-S score decreased from 4.4 ± 0.7 to 2.2 ± 1.1 and mean ± SD PDQ-D score decreased from 42.1 ± 18.8 to 13.4 ± 13.0. By Month 3, response and remission rates reached 80.8% and 59.0%, respectively. Work productivity loss decreased from 73.6% to 30.5%, while activity impairment decreased from 71.5% to 24.6%. Positive correlations were observed between PHQ-9, PDQ-D, and WPAI work productivity loss and activity impairment. By Month 3, 82.0% of patients were either not depressed or only mildly depressed (PHQ-9 score ≤9). CONCLUSION: In real-world clinical settings, vortioxetine was effective in reducing depression severity and improving cognitive function and work productivity in SEA patients with major depression.
OBJECTIVE: The REVIDA study aimed to assess the evolution of major depression symptoms in South East Asian (SEA) patients treated with vortioxetine for major depression in real-world clinical practice. METHODS: This non-interventional study was conducted from August 2016 to April 2017. A total of 138 patients (aged 18-65 years) with an active episode of major depression were recruited from Malaysia, Philippines, Singapore and Thailand. Vortioxetine was initiated on the first visit and patients were followed for 3 months. Depression severity was assessed using the PHQ-9 questionnaire (patient assessed) and CGI-S scale (physician assessed); cognitive function was assessed with the PDQ-D questionnaire; work productivity and activity impairment (WPAI) was assessed with the WPAI questionnaire. RESULTS: At baseline, 89.9% of patients were moderately to severely depressed (PHQ-9 score ≥10). During the 3 month treatment period, mean ± SD PHQ-9 score decreased from 18.7 ± 5.7 to 5.0 ± 5.3, mean ± SD CGI-S score decreased from 4.4 ± 0.7 to 2.2 ± 1.1 and mean ± SD PDQ-D score decreased from 42.1 ± 18.8 to 13.4 ± 13.0. By Month 3, response and remission rates reached 80.8% and 59.0%, respectively. Work productivity loss decreased from 73.6% to 30.5%, while activity impairment decreased from 71.5% to 24.6%. Positive correlations were observed between PHQ-9, PDQ-D, and WPAI work productivity loss and activity impairment. By Month 3, 82.0% of patients were either not depressed or only mildly depressed (PHQ-9 score ≤9). CONCLUSION: In real-world clinical settings, vortioxetine was effective in reducing depression severity and improving cognitive function and work productivity in SEA patients with major depression.
Entities:
Keywords:
Antidepressant; major depressive disorder; real-world study; vortioxetine
Authors: Gregory W Mattingly; Hongye Ren; Michael Cronquist Christensen; Martin A Katzman; Mircea Polosan; Kenneth Simonsen; Lene Hammer-Helmich Journal: Front Psychiatry Date: 2022-03-09 Impact factor: 4.157